Amgen 20170542
Posted by: Georgia Retina in
Research Title: A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration Sponsor: Amgen Principal Investigator: Atul Sharma, MD Description: The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration….
Read More
Apellis APL2-303 DERBY
Posted by: Georgia Retina in
Research Title: A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Sponsor: Apellis Pharmaceuticals, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to…
Read More Gemini GEM-NH-001 Clarity 1
Posted by: Georgia Retina in
Research Title: A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (AMD) Sponsor: Gemini Therapeutics, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This is a prospective, multicenter, longitudinal registry, conducted in subjects…
Read More Genentech GR40349 YOSEMITE
Posted by: Georgia Retina in
Research Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Diabetic Macular Edema (YOSEMITE). Sponsor: Genentech, Inc. / Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in…
Read More Genentech GR40548 ARCHWAY
Posted by: Georgia Retina in
Research Title: Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration Sponsor: Genentech, Inc. / Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed…
Read More Genentech GR40973 Gallego
Posted by: Georgia Retina in
Research Title: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO) Sponsor: Genentech, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of RO7171009 administered every 4…
Read More NGM Biopharmaceuticals NGM621-GA-201 CATALINA
Posted by: Georgia Retina in
Research Title: A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Sponsor: NGM Biopharmaceuticals, Inc. Principal Investigator: Robert A. Stoltz, MD, PhD Description: This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants…
Read More Novartis CRTH258C2302 Raven
Posted by: Georgia Retina in
Research Title: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN) Sponsor: Novartis Pharmaceuticals Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: Following a 4-week maximum screening period, patients will be randomized and…
Read More Gyroscope Therapeutics GTSCOPE
Posted by: Georgia Retina in
Research Title: A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) Sponsor: Gyroscope Therapeutics Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: Prospective, observational study to evaluate the natural progression of anatomical and functional visual parameters in genetically defined subjects with GA due to AMD. Start Date: March 2019 Recruitment: Enrolling…
Read More Iveric Bio ISEE2008 GATHER2
Posted by: Georgia Retina in
Research Title: A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Sponsor: IVERIC bio, Inc. Principal Investigator: Atul Sharma, MD Description: The objectives of this study are to evaluate the safety and efficacy…
Read More 
